Next Article in Journal
Efficient and Practical Correlation Filter Tracking
Next Article in Special Issue
Magnetic Lateral Flow Immunoassay for Small Extracellular Vesicles Quantification: Application to Colorectal Cancer Biomarker Detection
Previous Article in Journal
Energy-Efficient Wireless Sensor Network with an Unequal Clustering Protocol Based on a Balanced Energy Method (EEUCB)
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy

1
Department of Electronic Engineering, Gachon University, Seongnam-si, Gyeonggi-do 13120, Korea
2
Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Korea
*
Author to whom correspondence should be addressed.
Sensors 2021, 21(3), 788; https://doi.org/10.3390/s21030788
Submission received: 28 December 2020 / Revised: 18 January 2021 / Accepted: 22 January 2021 / Published: 25 January 2021
(This article belongs to the Special Issue Electrochemical Sensors and (Bio)assays for Health Applications)

Abstract

:
Aggregation of amyloid-β (aβ) peptides into toxic oligomers, fibrils, and plaques is central in the molecular pathogenesis of Alzheimer’s disease (AD) and is the primary focus of AD diagnostics. Disaggregation or elimination of toxic aβ aggregates in patients is important for delaying the progression of neurodegenerative disorders in AD. Recently, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) was introduced as a chemical agent that binds with toxic aβ aggregates and transforms them into monomers to reduce the negative effects of aβ aggregates in the brain. However, the mechanism of aβ disaggregation by EPPS has not yet been completely clarified. In this study, an electrochemical impedimetric immunosensor for aβ diagnostics was developed by immobilizing a specific anti-amyloid-β (aβ) antibody onto a self-assembled monolayer functionalized with a new interdigitated chain-shaped electrode (anti-aβ/SAM/ICE). To investigate the ability of EPPS in recognizing AD by extricating aβ aggregation, commercially available aβ aggregates (aβagg) were used. Electrochemical impedance spectroscopy was used to probe the changes in charge transfer resistance (Rct) of the immunosensor after the specific binding of biosensor with aβagg. The subsequent incubation of the aβagg complex with a specific concentration of EPPS at different time intervals divulged AD progression. The decline in the Rct of the immunosensor started at 10 min of EPPS incubation and continued to decrease gradually from 20 min, indicating that the accumulation of aβagg on the surface of the anti-aβ/SAM/ICE sensor has been extricated. Here, the kinetic disaggregation rate k value of aβagg was found to be 0.038. This innovative study using electrochemical measurement to investigate the mechanism of aβagg disaggregation by EPPS could provide a new perspective in monitoring the disaggregation periods of aβagg from oligomeric to monomeric form, and then support for the prediction and handling AD symptoms at different stages after treatment by a drug, EPPS.

1. Introduction

The deposition of the amyloid-β (aβ) protein in the cortex of the brain is reported as a leading cause of Alzheimer’s disease (AD), the most common form of dementia [1]. According to the amyloid cascade hypothesis, aβ peptides tend to aggregate and coalesce into toxic insoluble oligomers and fibrils in plaques, which may cause decline in synaptic function and nerve cell damage [2,3].
Aggregation of aβ gradually increases throughout the brain, which leads to neurodegeneration, starting from mild to moderate symptoms in earlier Alzheimer’s stages, and finally dementia [3,4]. Many efforts have been made to control and prevent Alzheimer’s progression by inhibiting and reducing the aggregation of aβ. For instance, laser-induced destruction [5], ultrasonic treatment [6], temperature-induced dissociation [7], pulsed radio-frequency cold atmospheric plasma jet [8], and drug treatments [9,10] have all been used to eliminate the aggregation of aβ. Among these approaches, drug treatment is the most-studied means of reducing or eliminating aβ aggregation, as these agents provide the most practical strategy to target the aβ aggregates within the body. Some natural chemical compounds such as theaflavins from black tea, epigallocatechin 3-gallate from green tea, and components from coffee showed an inhibitory effect on the aggregation of aβ [11,12,13]. However, the precise mechanism of interaction between these agents and aβ aggregates remains uncertain, and none of these have been used to treat AD clinically.
Recently, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) has been acknowledged as a promising drug candidate for dissociating and converting aβ aggregates into monomers. A study on a mouse model of Alzheimer’s aβ plaques found that EPPS can contribute to the breakdown of the plaques, which can alleviate some of the AD symptoms in mice [14]. Despite its significance, the detailed mechanism of EPPS on the disaggregation of aβ aggregates has not been thoroughly elucidated.
Electrochemical immunosensors offer rapid response, high sensitivity, and selective detection of aβ at very low concentrations [15,16,17,18]. In this report, we created an impedimetric immunosensor for the diagnosis of aβ aggregates (aβagg) and aβ peptide (aβpep). It was produce by the immobilization of a specific anti-aβ antibody on a self-assembled monolayer functionalized with a new interdigitated chain-shaped electrode (anti-aβ/SAM/ICE). This was then used to monitor the effect of EPPS on the disaggregation aβagg. After the anti-aβ/SAM/ICE biosensor bound with aβagg, forming the aβagg complex, the aβagg complex was then incubated with a specific concentration of EPPS at different time intervals to divulge the disaggregation progress of aβagg. Electrochemical impedance spectroscopy (EIS) was used as a tool to confirm the changes in charge transfer resistance (Rct) of the immunosensor after forming the complex and EPPS treatment. We established a new method for studying the mechanism of EPPS-induced kinetic disaggregation of aβagg by analyzing the EIS results from this study, leading to new insights in the diagnostics and treatment of AD symptoms at various levels.

2. Materials and Methods

2.1. Materials

AggreSureᵀᴹ Amyloid-β 1–42 aggregate (aβagg) is bought from AnaSpec (Fremont, CA 94555, USA). Anti-aβ antibody ab126649 (anti-aβ), Amyloid beta peptide 1–42, human, ab120301 (aβpep) are bought from Abcam (Seoul, Korea).
De-ionized (DI) water is gained from Milli-Q system. Phosphate buffer saline (PBS, pH 7.4) is received from Tech-Innovation.
4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS, BioXtra, ≥99.5% [titration]), EDC hydrochloride (crystalline, ≥98.0%), 6-mercaptohexanoic acid (MHA, 90%), 1-hydroxy-2,5-pyrrolidinedione (NHS, 98.0%), potassium ferrocyanide/ferricyanide ([Fe(CN)6]3−/4−), bovine serum albumin (BSA, 0.5% in 1 × PBS, pH 7.4) are obtained from Sigma Aldrich (Seoul, Korea).

2.2. Development of the Immunosensor for Monitoring the Impact of EPPS on the Disaggregation of aβagg

On a glass transparency substrate (13.5 × 16.0 × 0.5 mm), an interdigitated chain-shaped electrode (ICE) is made. Ti and Au have been deposited in an electron beam-evaporator with electrodes 25 nm and 50 nm of thickness. The lift-off procedure then formed the coupled electrode finger consisting of 5 μm distance and width for working and reference electrodes. The ICE was then cleaned with 100% ethanol, DI water, and dried in nitrogen gas flow to prepare for the development of the immunosensor. Schematic of the fabrication and microscope image of ICE are displayed in Figure 1.
The development of the immunosensor for diagnosis of aβagg is displayed in Figure 2. A self-assembled monolayer (SAM) has been mounted on the purified ICE gold surface in 100 mM MHA for 24 hours at room temperature. A solution of 75 mM EDC and 5 mM NHS was then incubated with the SAM-modified electrode to activate the carboxyl group for antibody binding. Then, ten anti-aβ antibody microliters (100 μg·mL−1) in PBS (pH ~ 7.4) are dripped off into a modified electrode and incubated for 1 hour in a moist compartment at 4 °C. Therefore, the EDC/NHS-activated SAM molecules on the modified electrodes were attached to the anti-aβ antibody through the amino group. After that, nonspecific adsorption was blocked by incubating with BSA (0.5% in 1 × PBS, pH 7.4) for 20 min at 4 °C to develop the anti-aβ/SAM/ICE biosensor. The developed anti-aβ/SAM/ICE biosensor was then incubated with aβagg (in PBS (pH ~ 7.4)) for 20 min at room temperature for the recognition of aβagg.
To monitor the effect of EPPS on the kinetics disaggregation of aβagg, the anti-aβ/SAM/ICE biosensor was incubated with aβagg (2.5 × 10−3 mg·mL−1) for 20 min to enable a specific binding between the antibody and antigen, called the aβagg complex. Subsequently, the aβagg complex was incubated with 20 mM·L−1 of EPPS for various time periods to study the disaggregation process of aβagg by electrochemical impedance measurement.

2.3. EIS Measurements and Functional Group Characterization

EIS was performed using EC-Lab (SP-200, Bio-Logic, France) in 5 mM [Fe(CN)6]3−/4− in PBS (pH 7.4) at each step of the anti-aβ/SAM/ICE biosensor development and various time intervals of the disaggregation process of aβagg. The EIS data was obtained by putting on a 10 mV of sinus amplitude which satisfy the linear properties of electrical response of the object between the working and reference electrode from 100 mHz to 1 MHz of range frequency. Z-Fit software (EC-Lab, Bio-Logic, France) was used to fit the obtained EIS data through by the Randle’s equivalent circuit.
Fourier-transform infrared (FT-IR) spectra was characterized by using Jasco-4600 FTIR (USA) spectrometer to confirm the functional groups for the fabrication steps of the anti-aβ/SAM/ICE biosensor.

3. Results and Discussion

3.1. Investigating the Development of Impedimetric Immunosensor

As shown in Figure 3a, EIS measurements were carried out to determine the Nyquist-plots with the imaginary impedance component (-Im(Z)) plotted with the actual impedance component (Re(Z)) to confirm the successful modification of substantial ingredients to the electrode surface at different stages of the development the anti-aβ/SAM/ICE immunosensor.
The equivalent circuit model of Randle insert into Figure 3a was used to fit the Nyquist plot data, showing three EIS parameters, including the C (capacitance for the electrode-solution interface element), Rct (interfacial charge-transfer resistance that corresponds to the semicircular diameter in the Nyquist plot), and Rs (solution resistance).
The obtained fitting value of Rct from Figure 3a was displayed in Figure 3b and Table 1. After SAM deposition that can be attributed to the −COO‾ group and the carbon chain SAM which prevents the transfer of the negative charged [Fe(CN)6]3−/4− redox couple to the electrode surface, the value of Rct has increased dramatically. Then, Rct decreased after the EDC–NHS layer was deposited on the SAM-modified electrode, suggesting that the −COO‾ groups of SAM were activated with the EDC–NHS carbodiimide coupler, the formation of succinimide ester on the modified electrode surface of SAM allows fast electron transfer between the electrode and the interface [19]. The two continuous immobilization steps of anti-aβ and BSA showed an increase in Rct due to the binding of a specific material on the sensor surface which enhanced its surface resistance [20], demonstrating that the surface of the biosensor was covered by specific materials.
Fourier-transform infrared (FT-IR) spectra was also used to confirm the fabrication of the anti-aβ/SAM/ICE biosensor, and the results were displayed in Figure 4. The FT-IR result of the SAM-modified ICE showed the typical peaks near 1601 cm−1 of carbonyl from the carboxylic acid moiety on the alkanethiols of SAM [21], indicating the immobilization of SAM on the ICE. FT-IR result of the immobilized anti-aβ on the EDC-NHS coupler activated SAM-modified ICE (blue curve in Figure 4) showed the typical peaks of protein at near 3374 cm−1 of N-H stretching of amide II [22], 2925 and 2849 cm−1 of C-H stretching of -CH2 of protein [23,24], 920 cm−1 of C-O stretching [25], and 602 cm−1 of N-H deformation [22], which demonstrated the successful development of the anti-aβ/SAM/ICE biosensor.

3.2. Monitoring the Effect of EPPS on aβ Disaggregation

EPPS was used to target the disaggregation of aβagg into its monomeric form. To confirm whether EPPS had an effect on the disaggregation of aβagg, EIS was used to explore the change in Rct of the specific anti-aβ/SAM/ICE biosensor for recognizing aβ during incubation with EPPS at different time intervals.
Firstly, the impact of EPPS on the anti-aβ antibody was studied. EIS measurements of the anti-aβ/SAM/ICE biosensor after incubation with 20 mM·L−1 EPPS at different time intervals are displayed in Figure 5. The Nyquist plots in Figure 5a did not change significantly after treatment with EPPS. Using Randle’s equivalent circuit to fit the EIS data of Nyquist plots in Figure 5a, the Rct value was generated that serve to normalize the response of the anti-aβ/SAM/ICE biosensor to the EPPS treatment at 10, 20, 30, 40, 50 min in Figure 5b, where R0 represents the Rct value of the biosensor with the immobilization of anti-aβ antibody, and Ra represents the Rct value of the anti-aβ/SAM/ICE biosensor within the treatment of EPPS. The normalized value (Ra − R0)/R0 of the anti-aβ/SAM/ICE biosensor in Figure 5b did not change significantly after treatment with EPPS at various time periods, indicating that EPPS did not affect the anti-aβ antibody. The fitting EIS data were shown in Table 2.
Gel electrophoresis method [26] was used to confirm the aggregation state of aβ in this manuscript. As seen in Figure 6, the gel electrophoresis result of aβagg showed the molecular-weight ranging of 11 kDa for oligomer form, which corresponds to a smear band containing monomers and low-molecular-weight oligomers ranging between 4 and 18 kDa in size of aβ oligomers [27], demonstrating the oligomeric form of aβagg in this research.
The process of disaggregation of aβagg by EPPS at different time intervals is described in Section 2.2. Initially, the anti-aβ/SAM/ICE biosensor was incubated with aβagg (2.5 × 10−3 mg·mL−1) for 20 min in the absence of EPPS and measured via EIS to examine the aβ recognition of the biosensor. EIS measurements showed an increase in the diameter and height of the semicircle in the Nyquist plot, corresponding to the enhanced Rct after the anti-aβ/SAM/ICE biosensor was incubated with aβagg, which is marked by 0 min in Figure 7a. This enhancement of Rct is ascribed to the hindrance of electron transfer between the [Fe(CN)6]3−/4− redox couple and the electrode surface due to successful specific binding between anti-aβ antibody and aβagg, called aβagg complex on the surface of the sensor. The biosensor with the aβagg complex was subsequently incubated for different time periods (10, 20, 30, 40, and 50 min) with 20 mM·L−1 of EPPS and was used for EIS measurements. As shown in Figure 7a, after 10 min of incubation in EPPS, the Rct of the biosensor with the aβagg complex in the Nyquist plot showed an increase in the height and diameter of the semicircle, and the Nyquist plot remained the same for the next 20 min of incubation with EPPS, which indicated that the [Fe(CN)6]3−/4− ion transport towards the electrode surface was blocked due to excessive aβ on the electrode surface. These results implied that the disaggregation of aβagg started after 10 min of incubation with EPPS and was continuously maintained after 20 min of incubation. This disaggregation process converted the aβagg into small aβ monomers, and still retained a certain amount of aβagg, creating an abundant compound of aβ monomers and aβagg on the biosensor surface, as delineated in Figure 8a, which hindered the transportation of [Fe(CN)6]3−/4− redox couple to the electrode surface, leading to an increase in Rct. Figure 7a showed the decline in Rct after treatment with EPPS at 30 min, which manifested the disaggregation of the remaining aβagg into several monomeric aβ molecules on the sensor surface, suggesting that the movement of ion [Fe(CN)6]3−/4− toward the electrode surface was facilitated; the impeded ion [Fe(CN)6]3−/4− movement was caused by the presence of a dense aβagg that was reduced by converting the aβagg molecules into aβ monomers, leading to the expansion of spacing between the specific aβ molecules on the electrode surface, resulting in facilitating transport of redox couple [Fe(CN)6]3−/4−. This decline of Rct continued to occur at 40 and 50 min during EPPS treatment, which indicated the continuous disaggregation of aβagg. A graphical description of the disaggregation process of aβagg by EPPS at various time intervals is shown in Figure 8a. The response of aβagg to EPPS treatment at time periods was evaluated by normalizing the Rct value of Figure 7a and plotted against time, as (Rb − Ri)/Ri in Figure 7b, where Ri represents the Rct of the biosensor with the immobilization of aβagg, and Rb represents the Rct of the biosensor with the immobilization of aβagg within the EPPS treatment. The normalized value (Rb − Ri)/Ri in Figure 7b increased after 10 min of EPPS treatment, remained stable after 20 min, and gradually decreased over the 30, 40, and 50 min points, which indicated the disaggregation process of aβagg at different time intervals starting at 10 min and confirmed the effect of EPPS on aβagg disaggregation, corresponding to the results and explanation in Figure 7a. A detailed graphical description of the disaggregation process of aβagg by EPPS at various time intervals is provided in Figure 8a. The fitting EIS data were shown in Table 3.
The effect of EPPS on the aβ 1–42 peptide (aβpep), a long peptide of 1–42 amino acids, was also studied for comparison with the obtained results of aβagg, which are mentioned above. The experiment of aβpep treatment in EPPS was carried out through similar processes as described in Section 2 with aβagg replaced by aβpep. Nyquist plot of EIS result in Figure 9a show an increase in Rct of the biosensor anti-aβ/SAM/ICE after 20 min of incubation with aβpep. This increment of Rct is expected due to the repulsion between the negative charge of immobilized aβpep antigen on the anti-aβ/SAM/ICE biosensor with redox couple, that could prevent the redox couple from reaching the SAM-modified electrode, confirming the successful binding between anti-aβ and aβpep [28]. The Rct of the biosensor with the immobilized aβpep remained the same after 10 min of treatment in EPPS, indicating that aβpep was not affected by EPPS for the initial 10 min treatment. Rct significantly decreased after 20 and 30 min of subsequent EPPS treatment, indicating the facilitating electron transfer at the electrode interface. This decrease of Rct may be attributed to the fragmentation of aβpep by EPPS, leading to the formation of ion-complexed amyloid beta with [Fe(CN)6]3−/4− [29,30], which results in the decreasing of Rct and enhancing of electrochemical property of the sensor at 20 min treatment, and at more treatment time of 30 min [16]. The normalized result (Rb − Ri)/Ri is displayed in Figure 9b, where Ri represents the Rct of the biosensor with the immobilization of aβpep, and Rb represents the Rct of the biosensor with the immobilization of aβpep within the EPPS treatment, which corresponds with the data of Nyquist plots in Figure 9a. The (Rb − Ri)/Ri was stable after 10 min, and rapidly decreased over the 20 and 30 min points following EPPS treatment. Figure 8b shows the effect of EPPS treatment on aβpep, and EIS results are shown in Figure 9. The fitting EIS data were shown in Table 4.
By examining the EIS results of aβagg and aβpep in the treatment with EPPS in this study, it is observed that EPPS affects the disaggregation of aβagg gradually and leads to the establishment of a disaggregation mechanism, as shown in Figure 8, while EPPS causes rapid disruption of aβpep.

3.3. Kinetic Disaggregation Rate k

The kinetic disaggregation rate k of protein is an important parameter in evaluating the functioning of neurodegenerative diseases [31]. However, there have not been report on the k value for aβagg at present. To estimate the disaggregation rate k value for aβagg, the normalized data for the treatments of aβagg and aβpep in EPPS were plotted and fitted versus time, as shown in Figure 10. Data for the disaggregation experiment aβagg represent the best fit of the data to a single-exponential function y = 0.1490.048exp(0.038x), whereas data for the treatment aβpep in EPPS express a linear fit function y = 0.2710.027x. According to the studies of kinetic disaggregation of proteins, the fitting data for protein disaggregation has been expressed by an exponential function F = y0 + Aexp(−kt) [31,32], where k represents the disaggregation rate. Consequently, the disaggregation rate k of aβagg was determined to be 0.038 by our method, providing a reference parameter for the disaggregation of aβagg for future studies.

4. Conclusions

A new concept of measuring aβagg disaggregation following treatment with EPPS via EIS signaling was introduced in this report. An electrochemical impedimetric immunosensor was developed to monitor EIS signals at the disaggregation stages of aβagg during treatment with EPPS at different time intervals. The obtained EIS results confirmed that the disaggregation of aβagg by treatment in EPPS occurred after 10 min, and this disaggregation process continued gradually over the next 50 min. A single exponential function for aβagg disaggregation was also found in this report, with a kinetic disaggregation rate (k) value of 0.038. The data indicated the successful application of EIS measurement in monitoring and establishing the mechanism for the impact of EPPS on the disaggregation of aβagg, which may lead to new insights in the diagnosis and treatment of signs of AD at various phases.

Author Contributions

Conceptualization, writing—original draft preparation, H.T.N.L.; methodology, H.T.N.L.; writing—review and editing, supervision, S.C. All authors have read and agreed to the published version of the manuscript.

Funding

The work was supported by the National Research Foundation of Korea, Republic of Korea (Grant No. NRF-2018M3A9F1023691, 2020M3A9E410438511, and 2019R1G1A1100610); R&BD Program through the INNOPOLIS funded by Ministry of Science and ICT (2020-IT-RD-0050).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Murphy, M.P.; LeVine, H., III. Alzheimer’s Disease and the β-Amyloid Peptide. J. Alzheimer’s Dis. 2010, 19, 311. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Blennow, K.; Mattsson, N.; Schöll, M.; Hansson, O.; Zetterberg, H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol. Sci. 2015, 36, 297–309. [Google Scholar] [CrossRef] [PubMed]
  3. Clifford, R.J., Jr.; Bennett, D.A.; Blennow, K.; Carrillod, M.C.; Dunne, B.; Haeberleinf, S.B.; Holtzmang, D.M.; Jagusth, W.; Jesseni, F.; Karlawishj, J.; et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018, 14, 535–562. [Google Scholar]
  4. O’Brien, R.J.; Wong, P.C. Amyloid Precursor Protein Processing and Alzheimer’s Disease. Annu. Rev. Neurosci. 2011, 34, 185–204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Yagi, H.; Ozawa, D.; Sakurai, K.; Kawakami, T.; Kuyama, H.; Nishimura, O.; Shimanouchi, T.; Kuboi, R.; Naiki, H.; Goto, Y. Laser-induced Propagation and Destruction of Amyloid β Fibrils. J. Biol. Chem. 2010, 285, 19660–19667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Lee, W.S.; Jung, H.H.; Son, M.G.; Lee, H.B.; Kwak, T.J.; Lee, G.D.; Kim, C.H.S.; Lee, W.; Yoon, D.S. Characterization of the regrowth behavior of amyloid-like fragmented fibrils decomposed by ultrasonic treatment. RSC Adv. 2014, 4, 56561–56566. [Google Scholar] [CrossRef]
  7. Takeda, T.; Klimov, D.K. Temperature-Induced Dissociation of Aβ Monomers from Amyloid Fibril. Biophys. J. 2008, 95, 1758–1772. [Google Scholar] [CrossRef] [Green Version]
  8. Bayliss, D.L.; Walsh, J.L.; Shama, G.; Iza, F.; Kong, M.G. Reduction and degradation of amyloid aggregates by a pulsed radio-frequency cold atmospheric plasma jet. New J. Phys. 2009, 11, 115024. [Google Scholar] [CrossRef] [Green Version]
  9. Sacchettini, J.C.; Kelly, J.W. Therapeutic strategies for human amyloid diseases. Nat. Rev. Drug Discov. 2002, 1, 267–275. [Google Scholar] [CrossRef]
  10. Karran, E.; Mercken, M.; Strooper, B.D. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisalfor the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10, 698–712. [Google Scholar] [CrossRef]
  11. Gerlinde, G.; Albrecht, O.; Mario, L.; Ronald, F.F.; Erich, E.W.; Jan, B. Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils. Biochemistry 2011, 50, 10624–10636. [Google Scholar]
  12. Lee, J.W.; Lee, Y.K.; Ban, J.O.; Ha, T.Y.; Yun, Y.P.; Han, S.B.; Oh, K.W.; Hong, J.T. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J. Nutr. 2009, 139, 1987–1993. [Google Scholar] [CrossRef] [PubMed]
  13. Cheng, B.; Liu, X.; Gong, H.; Huang, L.; Chen, H.; Zhang, X.; Li, C.; Yang, M.; Ma, B.; Jiao, L.; et al. Coffee Components Inhibit Amyloid Formation of Human Islet Amyloid Polypeptide in Vitro: Possible Link between Coffee Consumption and Diabetes Mellitus. J. Agric. Food Chem. 2011, 59, 13147–13155. [Google Scholar] [CrossRef] [PubMed]
  14. Kim, H.Y.; Kim, H.V.; Jo, S.M.; Lee, C.J.; Choi, S.Y.; Kim, D.J.; Kim, Y.S. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques. Nat. Commun. 2015, 6, 8997. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Yoo, Y.K.; Kim, J.S.; Kim, G.; Kim, Y.S.; Kim, H.Y.; Lee, S.J.; Cho, W.W.; Kim, S.S.; Lee, S.M.; Lee, B.C.; et al. A highly sensitive plasma-based amyloid-β detection system through medium-changing and noise cancellation system for early diagnosis of the Alzheimer’s disease. Sci. Rep. 2017, 7, 8882. [Google Scholar] [CrossRef] [Green Version]
  16. Rushworth, J.V.; Ahmed, A.; Griffiths, H.H.; Pollock, N.M.; Hooper, N.M.; Millner, P.A. A label-free electrical impedimetric biosensor for the specific detection of Alzheimer’s amyloid-beta oligomers. Biosens. Bioelectron. 2014, 56, 83–90. [Google Scholar] [CrossRef]
  17. Xing, Y.; Feng, X.Z.; Zhang, L.; Hou, J.; Han, G.C.; Chen, Z. A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles. Int. J. Nanomed. 2017, 12, 3171–3179. [Google Scholar] [CrossRef] [Green Version]
  18. Truong, T.N.L.; Takamura, Y.; Tamiya, E.; Vestergaard, M.C. Modified screen printed electrode for development of a highly sensitive label-free impedimetric immunosensor to detect amyloid beta peptides. Anal. Chim. Acta 2015, 892, 69–76. [Google Scholar]
  19. Chinnadayyala, S.R.; Cho, S.B. Electrochemical Immunosensor for the Early Detection of Rheumatoid Arthritis Biomarker: Anti-Cyclic Citrullinated Peptide Antibody in Human Serum Based on Avidin-Biotin System. Sensors 2021, 21, 124. [Google Scholar] [CrossRef]
  20. Martic, S.; Rains, M.K.; Kraatz, H.B. Probing copper/tau protein interactions electrochemically. Anal. Biochem. 2013, 442, 130–137. [Google Scholar] [CrossRef]
  21. Smith, B.C. Infrared Spectral Interpretation: A Systematic Approach; CRC Press Inc.: Boca Raton, FL, USA, 1998. [Google Scholar]
  22. Phan, L.M.T.; Kim, E.B.; Cheon, S.A.; Shim, T.S.; Kim, H.J.; Park, T.J. Reliable naked-eye detection of Mycobacterium tuberculosis antigen 85B using gold and copper nanoshell-enhanced immunoblotting techniques. Sens. Actuators B Chem. 2020, 317, 1282202. [Google Scholar] [CrossRef]
  23. Gaddam, S.A.; Kotakadi, V.S.; Gopal, D.V.R.S.; Rao, Y.S.; Reddy, A.V. Efficent and robust biofabrication of silver nanoparticles by Cassia alata leaf extract and their antimicrobial activity. J. Nanostruct. Chem. 2014, 4, 82. [Google Scholar] [CrossRef] [Green Version]
  24. Phan, L.M.T.; Rafique, R.; Baek, S.H.; Nguyen, T.P.; Park, K.Y.; Kim, E.B.; Kim, J.G.; Park, J.P.; Kailasa, S.K.; Kim, H.J.; et al. Gold-copper nanoshell dot-blot immunoassay for naked-eye sensitive detection of tuberculosis specific CFP-10 antigen. Biosens. Bioelectron. 2018, 121, 111–117. [Google Scholar] [CrossRef] [PubMed]
  25. Kumar, M.H.V.; Gupta, Y.K. Effect of different extracts of Centella asiatica on cognition and markers of oxidative stress in rats. J. Ethnopharmacol. 2002, 79, 253–260. [Google Scholar] [CrossRef]
  26. Smith, B.J. SDS Polyacrylamide Gel Electrophoresis of Proteins. Proteins Methods Mol. Biol. 1984, 1, 41–56. [Google Scholar] [PubMed]
  27. An, S.S.A.; Lee, B.S.; Yu, J.S.; Lim, K.T.; Kim, G.J.; Lee, R.; Kim, S.W.; Kang, S.M.; Park, Y.H.; Wang, M.J.; et al. Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42. Alzheimer’s Res. Ther. 2017, 9, 86. [Google Scholar] [CrossRef] [Green Version]
  28. Le, H.T.N.; Park, J.S.; Chinnadayyala, S.R.; Cho, S.B. Sensitive electrochemical detection of amyloid beta peptide in human serum using an interdigitated chain-shaped electrode. Biosens. Bioelectron. 2019, 144, 111694. [Google Scholar]
  29. Lermyte, F.; Everett, J.; Yuko, P.Y.L.; Wootton, C.A.; Brooks, J.; Barrow, M.P.; Telling, N.D.; Sadler, P.J.; O’Connor, P.B.; Collingwood, J.F. Metal Ion Binding to the Amyloid β Monomer Studied by Native Top-Down FTICR Mass Spectrometry. J. Am. Soc. Mass Spectrom. 2019, 30, 2123–2134. [Google Scholar] [CrossRef]
  30. Nair, G.N.; Perry, G.; Smith, M.A.; Reddy, V.P. NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid-β Peptide. J. Alzheimer’s Dis. 2010, 20, 57–66. [Google Scholar] [CrossRef]
  31. Cellmer, T.; Douma, R.; Huebner, A.; Prausnitz, J.; Blanch, H. Kinetic studies of protein L aggregation and disaggregation. Biophys. Chem. 2007, 125, 350–359. [Google Scholar] [CrossRef]
  32. Priezzhev, A.V.; Ryaboshapka, O.M.; Firsov, N.N.; Sirko, I.V. Aggregation and Disaggregation of Erythrocytes in Whole Blood: Study by Backscattering Technique. J. Biomed. Opt. 1999, 4, 76–84. [Google Scholar] [CrossRef] [PubMed]
Figure 1. (a) Fabrication of ICE, (b) Photograph of ICE, and (c) Scanning electron microscope image of chain-shaped gold finger of ICE.
Figure 1. (a) Fabrication of ICE, (b) Photograph of ICE, and (c) Scanning electron microscope image of chain-shaped gold finger of ICE.
Sensors 21 00788 g001
Figure 2. (ae) Development procedure the immunosensor anti-aβ/SAM/ICE for the recognition aβagg, (f) impedimetric measurement mechanism in the recognition aβagg by the developed biosensor anti-aβ/SAM/ICE, and (g) impedimetric results represent by Nyquist plot at each step of the development anti-aβ/SAM/ICE biosensor in the recognition aβagg.
Figure 2. (ae) Development procedure the immunosensor anti-aβ/SAM/ICE for the recognition aβagg, (f) impedimetric measurement mechanism in the recognition aβagg by the developed biosensor anti-aβ/SAM/ICE, and (g) impedimetric results represent by Nyquist plot at each step of the development anti-aβ/SAM/ICE biosensor in the recognition aβagg.
Sensors 21 00788 g002
Figure 3. EIS results at each step of the development of biosensor anti-aβ/SAM/ICE display in (a) Nyquist plots and (b) charge-transfer resistance (Rct).
Figure 3. EIS results at each step of the development of biosensor anti-aβ/SAM/ICE display in (a) Nyquist plots and (b) charge-transfer resistance (Rct).
Sensors 21 00788 g003
Figure 4. FT-IR results for the fabrication of the anti-aβ/SAM/ICE biosensor.
Figure 4. FT-IR results for the fabrication of the anti-aβ/SAM/ICE biosensor.
Sensors 21 00788 g004
Figure 5. EIS results of the biosensor anti-aβ/SAM/ICE with the treatment in EPPS at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Figure 5. EIS results of the biosensor anti-aβ/SAM/ICE with the treatment in EPPS at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Sensors 21 00788 g005
Figure 6. Gel electrophoresis results of aβpep and aβagg.
Figure 6. Gel electrophoresis results of aβpep and aβagg.
Sensors 21 00788 g006
Figure 7. EIS results monitoring the disaggregation aβagg with the treatment in EPPS at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Figure 7. EIS results monitoring the disaggregation aβagg with the treatment in EPPS at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Sensors 21 00788 g007
Figure 8. (a) Disaggregation mechanism of aβagg by EPPS, and (b) the impact of EPPS on aβpep.
Figure 8. (a) Disaggregation mechanism of aβagg by EPPS, and (b) the impact of EPPS on aβpep.
Sensors 21 00788 g008
Figure 9. EIS results monitoring the impact of EPPS on the aβpep at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Figure 9. EIS results monitoring the impact of EPPS on the aβpep at different time intervals display in (a) Nyquist plots and (b) Normalization of Rct. (n = 3; three data points shown).
Sensors 21 00788 g009
Figure 10. Fitting of two sets of disaggregation data for aβagg and aβpep, respectively; symbols and bars represent the average and standard deviation of the data (n = 3).
Figure 10. Fitting of two sets of disaggregation data for aβagg and aβpep, respectively; symbols and bars represent the average and standard deviation of the data (n = 3).
Sensors 21 00788 g010
Table 1. EIS parameters of the bare and modified ICE extrapolated by fitting the measured spectra to the equivalent circuit model shown in Figure 3a.
Table 1. EIS parameters of the bare and modified ICE extrapolated by fitting the measured spectra to the equivalent circuit model shown in Figure 3a.
ElectrodeRs (Ω)C (F)Rct (Ω)
ICE529.355.37 × 10−947,294
SAM522.877.78 × 10−9291,956
EDC-NHS524.969.69 × 10−977,691
anti-aβ52475.88 × 10−9191,820
BSA504.576.49 × 10−9255,926
Table 2. EIS parameters of the anti-aβ/SAM/ICE biosensor after treatment with EPPS at different time intervals, extrapolated by fitting the measured spectra in Figure 5a to the equivalent circuit model of Randle.
Table 2. EIS parameters of the anti-aβ/SAM/ICE biosensor after treatment with EPPS at different time intervals, extrapolated by fitting the measured spectra in Figure 5a to the equivalent circuit model of Randle.
ElectrodeRs (Ω)C (F)Rct (Ω)
Biosensor490.955.55 × 10−9715,084
10 min491.956.72 × 10−9724,551
20 min487.557.66 × 10−9726,538
30 min488.757.93 × 10−9724,904
40 min488.558.36 × 10−9743,262
50 min486.358.83 × 10−9730,896
Table 3. EIS parameters of the anti-aβ/SAM/ICE biosensor after incubating with aβagg, and then conduct to treatment with EPPS at different time intervals, extrapolated by fitting the measured spectra in Figure 7a to the equivalent circuit model of Randle.
Table 3. EIS parameters of the anti-aβ/SAM/ICE biosensor after incubating with aβagg, and then conduct to treatment with EPPS at different time intervals, extrapolated by fitting the measured spectra in Figure 7a to the equivalent circuit model of Randle.
ElectrodeRs (Ω)C (F)Rct (Ω)
Biosensor504.876.10 × 10−9228,331
agg (0 min)519.276.29 × 10−9331,631
10 min517.475.98 × 10−9366,841
20 min517.175.89 × 10−9363,145
30 min519.175.08 × 10−9334,918
40 min519.574.81 × 10−9307,364
50 min517.674.71 × 10−9274,678
Table 4. EIS parameters of the anti-aβ/SAM/ICE biosensor after incubating with aβpep, and then conduct to treatment with EPPS at different time intervals, extrapolated by fitting the measured spectra in Figure 9a to the equivalent circuit model of Randle.
Table 4. EIS parameters of the anti-aβ/SAM/ICE biosensor after incubating with aβpep, and then conduct to treatment with EPPS at different time intervals, extrapolated by fitting the measured spectra in Figure 9a to the equivalent circuit model of Randle.
ElectrodeRs (Ω)C (F)Rct (Ω)
Biosensor633.591.3 × 10−9205,978
pep (0 min) 63592.96 × 10−9289,018
10 min632.692.17 × 10−9289,110
20 min629.890.69 × 10−9209,893
30 min639.988.06 × 10−9129,281
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Le, H.T.N.; Cho, S. Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy. Sensors 2021, 21, 788. https://doi.org/10.3390/s21030788

AMA Style

Le HTN, Cho S. Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy. Sensors. 2021; 21(3):788. https://doi.org/10.3390/s21030788

Chicago/Turabian Style

Le, Hien T. Ngoc, and Sungbo Cho. 2021. "Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy" Sensors 21, no. 3: 788. https://doi.org/10.3390/s21030788

APA Style

Le, H. T. N., & Cho, S. (2021). Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy. Sensors, 21(3), 788. https://doi.org/10.3390/s21030788

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop